OligomicsTx selected for Edmonton Edge funding
OligomicsTx has received $100,000 for the development of its cutting-edge treatment for facioscapulohumeral muscular dystrophy (FSHD) The rare neuromuscular disease impacts 1 in 8,000 people worldwide with no approved treatments on the market EDMONTON, AB: The City of Edmonton announced today that OligomicsTx (“Oligomics”), a pre-clinical stage biotechnology company developing treatments for rare muscular dystrophies, has been […]
OligomicsTx wins StartupTNT’s 2024 Life Sciences Investment Summit
We are thrilled to have won at the Startup TNT Life Sciences Summit! We thank all the investors who took the time to evaluate and meet with the participating companies. We appreciate all of the work they did in due diligence to understand what we are trying to achieve and the lives we are looking […]
Toshifumi Yokota elected 2023 Fellow of the Canadian Academy of Health Sciences
Toshifumi (Toshi) Yokota, a professor of medical genetics in the Faculty of Medicine & Dentistry, has been elected as a 2023 Fellow of the Canadian Academy of Health Sciences (CAHS). Fellowship in the CAHS is considered one of the highest honours within Canada’s academic community. Fellows, who serve as unpaid volunteers, are nominated by their institutions […]
OligomicsTx co-founder and chief scientist receives BioAlberta’s scientific achievement and innovation award
Dr. Toshifumi Yokota has been selected for BioAlberta’s Scientific Achievement and Innovation Award. The award celebrates teams or individuals responsible for breakthrough innovations with commercial applications, and Dr. Yokota was one of two winners. Dr. Yokota was selected based on his seminal discoveries in antisense oligonucleotide (ASO) and gapmer therapies for muscular dystrophies like Duchenne […]